166 Genetically engineered tumor-infiltrating lymphocytes (cytoTIL15) exhibit IL-2-independent persistence and anti-tumor efficacy against melanoma in vivo
Main Authors: | Gabriel Helmlinger, Rachel Burga, Stanley Tam, Mithun Khattar, Scott Lajoie, Kyle Pedro, Colleen Foley, Alonso Villasmil Ocando, Jack Tremblay, Benjamin Primack, Meghan Langley, Dan Thornton, Emily Brideau, Theresa Ross, Gwen Wilmes, Sunandan Saha, Jeremy Tchaicha, Dhruv Sethi, Michelle Ols, Gary Vanasse, Shyam Subramanian, Jan ter Meulen |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-11-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Similar Items
-
348 TIL engineered with membrane-bound IL15 (cytoTIL15™) are enriched for tumor-associated antigen reactivity and demonstrate pharmacologically tunable expansion and persistence in the presence of TAA
by: Kyle Pedro, et al.
Published: (2023-11-01) -
Urinary filariasis masquerading as the bladder tumor: A case report with cyto-histological correlation
by: Shyama Jain, et al.
Published: (2015-01-01) -
A cyto-histo pathological correlation of bladder tumors in relation to smoking as a risk factor
by: Tanushree Satpathy, et al.
Published: (2018-07-01) -
Therapeutic efficacy of 166Holmium siloxane in microbrachytherapy of induced glioblastoma in minipig tumor model
by: Mehrdad Khoshnevis, et al.
Published: (2022-11-01) -
Cyto-Neurology in Ischemia
by: Cláudio Roque, et al.
Published: (2022-07-01)